US Stock MarketDetailed Quotes
TCRX TScan Therapeutics
- 4.520
- +0.260+6.10%
Close Nov 25 16:00 ET
- 4.520
- 0.0000.00%
Post 16:02 ET
241.24MMarket Cap-4757P/E (TTM)
4.720High4.300Low192.25KVolume4.360Open4.260Pre Close873.30KTurnover0.61%Turnover RatioLossP/E (Static)53.37MShares9.69052wk High1.05P/B141.47MFloat Cap3.92052wk Low--Dividend TTM31.30MShs Float14.710Historical High--Div YieldTTM9.86%Amplitude1.450Historical Low4.542Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
TScan Therapeutics Stock Forum
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houst...
Benzinga· 2 mins ago
NEWS
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
NEWS
TScan Therapeutics Announces Closing of Upsized Public Offering
No comment yet